Dear Editor,
There is a large body of evidence that antidepressants and cognitive therapy (CT) are beneficial for the treatment of social anxiety disorder (SAD) [1] . Although individual CT has recently been regarded as the first-choice treatment for SAD, antidepressants are still commonly used in clinical practice [2, 3] . Therefore, more work is required to garner evidence of next-step treatment options for SADs who have been ineffectively treated with antidepressants.
Only four studies have assessed augmentation or switching strategies for SADs who were refractory to antidepressants [4] [5] [6] [7] . Among these next-step strategies, individual CT as an adjunct to usual care has achieved the highest rates of treatment response (85.7%) and remission (47.6%) at the end of treatment [4] . Conversely, other medication augmentation/switching strategies had response rates of 48.3−70.0% and remission rates of 18.6−27.0% [5] [6] [7] . However, these studies have only assessed short-term treatment outcomes (the longest being 24 weeks).
In this paper, we report on 1-year follow-up data evaluating the long-term effectiveness of individual CT in addition to usual care for antidepressant-refractory SAD in our previous randomized controlled trial [4] , focusing on the adjunctive CT group. We supplementarily evaluated the cost-effectiveness of adjunctive CT, but the details are presented only in the online supplementary material (online suppl. Appendix; for all online suppl. material, see www.karger.com/doi/10.1159/000500108). the last observation forward for dropouts, these percentages were 95.2% (responded) and 57.1% (remitted). See online supplementary Results for more details.
The findings of this study indicate that the effects of adjunctive CT seemed to be well maintained 1 year after completion of treatment for measures of social anxiety, depression, generalized anxiety, and quality of life. The Pre to 1Y-FU treatment effect size of adjunctive CT was large (d = 2.66). The course of improvement demonstrates that antidepressant-refractory SADs exhibit substantial treatment gains immediately following treatment and that these are well maintained at the 1-month, 3-month, 6-month, and 1-year follow-up points. These results are consistent with the favorable long-term effects of individual CT for SADs observed in previous studies also carried out over at least 1 year, which did not target antidepressant-refractory patients [e.g., [8] [9] [10] . Thus, the findings of our study underscore the long-term benefits of adjunctive CT in improving social anxiety and other related symptoms, even in antidepressant-refractory cases.
The main limitations of the study are: (a) small sample size, (b) lack of follow-up clinical outcome data in the UC alone group, and (c) lack of follow-up information regarding concurrent medication in both groups. We also could not determine whether adjunctive CT itself, or other non-treatment-specific factors, contributed to greater clinical effectiveness. The current study intended to examine the additional value of CT to usual care but was not an examination of the effectiveness of CT itself. To evaluate outcomes with more confidence, a replication study is needed which employs a larger sample and obtains complete follow-up data including concurrent medication information. It would also be of interest to directly compare individual CT with other intervention-delivery methods (e.g., group based, internet based), with other forms of psychotherapy, and/or with other medications.
In conclusion, the results of this study suggest that adding CT to usual care for antidepressant-refractory SAD can produce substantial, maintained effects.
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